C. Crombie

A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial.

M. Stockler, N. Pavlakis, M. Millward, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features.

H. Gurney, M. Drummond, H. Lau, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II trial of gemcitabine and either day 1 or day 8 carboplatin for advanced non‐small‐cell lung cancer: Is thrombocytopenia predictable?

C. Karapetis, P. de Souza, W. I. Burns, 2009 .

Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.

K. Bradstock, M. Hertzberg, C. Crombie, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of megestrol acetate for metastatic carcinoma of the prostate.

D. Raghavan, D. Dalley, M. Rosen, 1987, British journal of urology.

Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile?

M. Stockler, M. Millward, B. Hughes, 2015, European journal of cancer.

Chemotherapy for small cell lung cancer: induction and reinduction with VOCA.

P. Bye, R. Stuart-Harris, D. Raghavan, 1987, Australian and New Zealand journal of medicine.

Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.

K. Bradstock, M. Hertzberg, C. Crombie, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Use of FISH in an aggressive diffuse large B cell lymphoma

C. Crombie, L. St Heaps, Arabella Smith, 2003, Pathology.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.